Alanine analogues of [D-Trp]CJ-15,208: Novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour

J. V. Aldrich, S. N. Senadheera, N. C. Ross, K. A. Reilley, M. L. Ganno, S. E. Eans, Thomas F. Murray, J. P. McLaughlin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Purpose The novel macrocyclic peptide cyclo[Phe-D-Pro-Phe-D- Trp] ([D-Trp]CJ-15,208) exhibits κ opioid (KOP) receptor antagonist activity in both in vitro and in vivo assays. The four alanine analogues of this peptide were synthesized and characterized both in vitro and in vivo to assess the contribution of different amino acid residues to the activity of [D-Trp]CJ-15,208. Experimental Approach The peptides were synthesized by a combination of solid phase peptide synthesis and cyclization in solution. The analogues were evaluated in vitro in receptor binding and functional assays, and in vivo with mice using a tail-withdrawal assay for antinociceptive and opioid antagonist activity. Mice demonstrating extinction of cocaine conditioned-place preference (CPP) were pretreated with selected analogues to evaluate prevention of stress or cocaine-induced reinstatement of CPP. Key Results The alanine analogues displayed pharmacological profiles in vivo distinctly different from [D-Trp]CJ-15,208. While the analogues exhibited varying opioid receptor affinities and κ and μ opioid receptor antagonist activity in vitro, they produced potent opioid receptor-mediated antinociception (ED50 = 0.28-4.19-nmol, i.c.v.) in vivo. Three of the analogues also displayed KOP receptor antagonist activity in vivo. Pretreatment with an analogue exhibiting both KOP receptor agonist and antagonist activity in vivo prevented both cocaine- and stress-induced reinstatement of cocaine-seeking behaviour in the CPP assay in a time-dependent manner. Conclusions and Implications These unusual macrocyclic peptides exhibit in vivo opioid activity profiles different from the parent compound and represent novel compounds for potential development as therapeutics for drug abuse and possibly as analgesics.

Original languageEnglish
Pages (from-to)3212-3222
Number of pages11
JournalBritish Journal of Pharmacology
Volume171
Issue number13
DOIs
StatePublished - 2014

Fingerprint

Cocaine
Alanine
Opioid Analgesics
Narcotic Antagonists
Peptides
Opioid Receptors
Pharmaceutical Preparations
Solid-Phase Synthesis Techniques
Cyclization
Substance-Related Disorders
Analgesics
Tail
Pharmacology
Amino Acids
phenylalanylproline
In Vitro Techniques
CJ 15,208
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Medicine(all)

Cite this

Alanine analogues of [D-Trp]CJ-15,208 : Novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour. / Aldrich, J. V.; Senadheera, S. N.; Ross, N. C.; Reilley, K. A.; Ganno, M. L.; Eans, S. E.; Murray, Thomas F.; McLaughlin, J. P.

In: British Journal of Pharmacology, Vol. 171, No. 13, 2014, p. 3212-3222.

Research output: Contribution to journalArticle

Aldrich, J. V. ; Senadheera, S. N. ; Ross, N. C. ; Reilley, K. A. ; Ganno, M. L. ; Eans, S. E. ; Murray, Thomas F. ; McLaughlin, J. P. / Alanine analogues of [D-Trp]CJ-15,208 : Novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour. In: British Journal of Pharmacology. 2014 ; Vol. 171, No. 13. pp. 3212-3222.
@article{5790c99d64d14af5bd77b8e8c94e7d26,
title = "Alanine analogues of [D-Trp]CJ-15,208: Novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour",
abstract = "Background and Purpose The novel macrocyclic peptide cyclo[Phe-D-Pro-Phe-D- Trp] ([D-Trp]CJ-15,208) exhibits κ opioid (KOP) receptor antagonist activity in both in vitro and in vivo assays. The four alanine analogues of this peptide were synthesized and characterized both in vitro and in vivo to assess the contribution of different amino acid residues to the activity of [D-Trp]CJ-15,208. Experimental Approach The peptides were synthesized by a combination of solid phase peptide synthesis and cyclization in solution. The analogues were evaluated in vitro in receptor binding and functional assays, and in vivo with mice using a tail-withdrawal assay for antinociceptive and opioid antagonist activity. Mice demonstrating extinction of cocaine conditioned-place preference (CPP) were pretreated with selected analogues to evaluate prevention of stress or cocaine-induced reinstatement of CPP. Key Results The alanine analogues displayed pharmacological profiles in vivo distinctly different from [D-Trp]CJ-15,208. While the analogues exhibited varying opioid receptor affinities and κ and μ opioid receptor antagonist activity in vitro, they produced potent opioid receptor-mediated antinociception (ED50 = 0.28-4.19-nmol, i.c.v.) in vivo. Three of the analogues also displayed KOP receptor antagonist activity in vivo. Pretreatment with an analogue exhibiting both KOP receptor agonist and antagonist activity in vivo prevented both cocaine- and stress-induced reinstatement of cocaine-seeking behaviour in the CPP assay in a time-dependent manner. Conclusions and Implications These unusual macrocyclic peptides exhibit in vivo opioid activity profiles different from the parent compound and represent novel compounds for potential development as therapeutics for drug abuse and possibly as analgesics.",
author = "Aldrich, {J. V.} and Senadheera, {S. N.} and Ross, {N. C.} and Reilley, {K. A.} and Ganno, {M. L.} and Eans, {S. E.} and Murray, {Thomas F.} and McLaughlin, {J. P.}",
year = "2014",
doi = "10.1111/bph.12664",
language = "English",
volume = "171",
pages = "3212--3222",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "13",

}

TY - JOUR

T1 - Alanine analogues of [D-Trp]CJ-15,208

T2 - Novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour

AU - Aldrich, J. V.

AU - Senadheera, S. N.

AU - Ross, N. C.

AU - Reilley, K. A.

AU - Ganno, M. L.

AU - Eans, S. E.

AU - Murray, Thomas F.

AU - McLaughlin, J. P.

PY - 2014

Y1 - 2014

N2 - Background and Purpose The novel macrocyclic peptide cyclo[Phe-D-Pro-Phe-D- Trp] ([D-Trp]CJ-15,208) exhibits κ opioid (KOP) receptor antagonist activity in both in vitro and in vivo assays. The four alanine analogues of this peptide were synthesized and characterized both in vitro and in vivo to assess the contribution of different amino acid residues to the activity of [D-Trp]CJ-15,208. Experimental Approach The peptides were synthesized by a combination of solid phase peptide synthesis and cyclization in solution. The analogues were evaluated in vitro in receptor binding and functional assays, and in vivo with mice using a tail-withdrawal assay for antinociceptive and opioid antagonist activity. Mice demonstrating extinction of cocaine conditioned-place preference (CPP) were pretreated with selected analogues to evaluate prevention of stress or cocaine-induced reinstatement of CPP. Key Results The alanine analogues displayed pharmacological profiles in vivo distinctly different from [D-Trp]CJ-15,208. While the analogues exhibited varying opioid receptor affinities and κ and μ opioid receptor antagonist activity in vitro, they produced potent opioid receptor-mediated antinociception (ED50 = 0.28-4.19-nmol, i.c.v.) in vivo. Three of the analogues also displayed KOP receptor antagonist activity in vivo. Pretreatment with an analogue exhibiting both KOP receptor agonist and antagonist activity in vivo prevented both cocaine- and stress-induced reinstatement of cocaine-seeking behaviour in the CPP assay in a time-dependent manner. Conclusions and Implications These unusual macrocyclic peptides exhibit in vivo opioid activity profiles different from the parent compound and represent novel compounds for potential development as therapeutics for drug abuse and possibly as analgesics.

AB - Background and Purpose The novel macrocyclic peptide cyclo[Phe-D-Pro-Phe-D- Trp] ([D-Trp]CJ-15,208) exhibits κ opioid (KOP) receptor antagonist activity in both in vitro and in vivo assays. The four alanine analogues of this peptide were synthesized and characterized both in vitro and in vivo to assess the contribution of different amino acid residues to the activity of [D-Trp]CJ-15,208. Experimental Approach The peptides were synthesized by a combination of solid phase peptide synthesis and cyclization in solution. The analogues were evaluated in vitro in receptor binding and functional assays, and in vivo with mice using a tail-withdrawal assay for antinociceptive and opioid antagonist activity. Mice demonstrating extinction of cocaine conditioned-place preference (CPP) were pretreated with selected analogues to evaluate prevention of stress or cocaine-induced reinstatement of CPP. Key Results The alanine analogues displayed pharmacological profiles in vivo distinctly different from [D-Trp]CJ-15,208. While the analogues exhibited varying opioid receptor affinities and κ and μ opioid receptor antagonist activity in vitro, they produced potent opioid receptor-mediated antinociception (ED50 = 0.28-4.19-nmol, i.c.v.) in vivo. Three of the analogues also displayed KOP receptor antagonist activity in vivo. Pretreatment with an analogue exhibiting both KOP receptor agonist and antagonist activity in vivo prevented both cocaine- and stress-induced reinstatement of cocaine-seeking behaviour in the CPP assay in a time-dependent manner. Conclusions and Implications These unusual macrocyclic peptides exhibit in vivo opioid activity profiles different from the parent compound and represent novel compounds for potential development as therapeutics for drug abuse and possibly as analgesics.

UR - http://www.scopus.com/inward/record.url?scp=84902190435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902190435&partnerID=8YFLogxK

U2 - 10.1111/bph.12664

DO - 10.1111/bph.12664

M3 - Article

C2 - 24588614

AN - SCOPUS:84902190435

VL - 171

SP - 3212

EP - 3222

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 13

ER -